Pharmacokinetics of High-dose Tigecycline in Critically Ill Patients

Critical Illness Clinical Trial

Official title:

Pharmacokinetics of High-dose Tigecycline in Critically Ill Patients: an Observational, Prospective Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03034174
• Other study ID #: KE-0254/258/2014
• Status: Completed
• Start date: January 15, 2017
• Est. completion date: October 10, 2018

Study information

• Verified date: November 2023
• Source: Medical University of Lublin
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The objective of this study is to describe the pharmacokinetics of tigecycline in critically ill patients receiving continuous venovenous haemodialysis (CVVHD) and to evaluate the frequency of pharmacokinetic/pharmacodynamic target attainment with high dosing strategy (200 mg loading dose and 100 mg/12h).

Description:

This is a prospective observational study performed on critically ill patients. Inclusion criteria are: severe sepsis on admission requiring broad-spectrum antibiotics. Both medical and surgical patients will be included. Any type of infections will be included (pulmonary, abdominal, urinary tract, etc.) Antibiotics regimen includes: tigecycline (200 mg every 12 hours intravenously), meropenem (2 grams every 8 hours intravenously).

Blood samples (3 mL) will be collected 2, 4, 8 and 12 hours after each dose of tigecycline for 3 consecutive days. The standard arterial canula will be used to obtain samples.

In each case CVVHD will be started and continued for at least 3 days' period. 30 minutes after a collection each sample will be centrifuged for 10 minutes at 3,000 rpms. Subsequently, supernatant will be collected and frozen.

Serum tigecycline concentration will be measured with high performance liquid chromatography.

Each patient's hemodynamics parameters will be recorded with the use of transpulmonary thermodilution technique (PICCO). Other therapies i.e.: ventilatory support, sedation, an antifungal agent will be given as required.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 37
• Est. completion date: October 10, 2018
• Est. primary completion date: December 15, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients who require ICU treatment due to severe sepsis

• age 18-80 years

• CVVHD treatment

• an eligible consent obtained from the patient or his/her attendant

Exclusion Criteria:

• allergy to tigecycline or meropenem

• contraindication to CVVHD

• lack of consent to participate in the study

• age of patients below 18 or above 80 years

Related Conditions & MeSH terms

• Antibiotic Resistant Infection
• Critical Illness
• Septic Shock

Locations

Country	Name	City	State
Poland	II Department of Anesthesia and Intensive Care, Medical University of Lublin	Lublin

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of Lublin

Country where clinical trial is conducted

Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serum concentration of tigecycline	Samples obtain from ICU patients 2, 4, 8 12 hours after each dose of tigecycline for 3 days.	72 hours for each patient from the tigecycline treatment initiation.